
Sunday, March 04, 2018 9:10:29 AM
Granowitz in the CC has already acknowledged that the placebo rate will be approximately 5% ( Co had previously stated that it could be as low as 5.2% )
Gabors response ( from memory ) was. ..." approx 5% could be anywhere between 4% and 6% ."...but I think Granowitz is skilled enough in modeling to be pretty accurate given the data they have access to .
Please understand some basic things:
a.) study design isn't equal with actual study / data
b.) study design is fixed by SPA in 2011 ... the p rate had not been changed ...
c.) The study design is about number of enrollees ... assuming RRR (R), Power (P), p rate (pr), etc (E) ... you will get the required number of patients (NoP) ... it was 6,990. "To protect against the possibility that the actual placebo event rate is lower than estimated" they added additional 1,000 to the design ("without having to modify the other sample size assumptions") ... resulted in "event rate in the placebo group could be 5.2% per year". eg.
R x P x x pr x E = Nop
If you increase the NoP, do not change R, P and E ... the pr will be lower, but both cases, pre and post change, is a fix / calculated number.
It is not debatable that the designed p rate is 5.2% (somewhere between 5.150% or 5.249% ... due to rounding) ... the assumption, the design was fixed 6.5 years ago.
Hopefully it helps you to understand what is the design, why the p rate is 5.2% and why CG's words refer to this ...
Re. Jardiance and other "improvements"
- you constantly forget that 40% only are in the US ...
- patients were randomized 1:1 between arms, so any effect affects both arms ... could change the ARR, but "not" the RRR (e.g. 6% vs 3% and 4% vs 2% have the same RRR ... 50%)
- despite your reference to "worldwide" Kaiser follow-up (SMS, etc.) the statistics do not reflect the "expected" improvements
Best,
G
#NEWMIAMI
Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Do Your Job
Volume: | 2,401,000 |
Day Range: | 0.396 - 0.46 |
Bid: | 0.4245 |
Ask: | 0.4265 |
Last Trade Time: | 3:14:38 PM EDT |
Total Trades: | 4,124 |
Recent AMRN News
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/07/2025 11:50:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2025 11:40:08 AM
- Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors • GlobeNewswire Inc. • 04/07/2025 11:30:00 AM
- Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist • GlobeNewswire Inc. • 03/31/2025 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/28/2025 08:45:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 08:45:07 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 03/26/2025 12:37:57 AM
- New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Car • GlobeNewswire Inc. • 03/19/2025 11:30:00 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 03/12/2025 11:46:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2025 11:05:07 AM
- Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program • GlobeNewswire Inc. • 03/12/2025 11:01:00 AM
- Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action • GlobeNewswire Inc. • 03/12/2025 11:00:00 AM
- Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering • GlobeNewswire Inc. • 02/27/2025 02:00:00 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Austria • GlobeNewswire Inc. • 02/25/2025 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 • GlobeNewswire Inc. • 02/19/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 09:15:07 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Italy • GlobeNewswire Inc. • 12/16/2024 12:00:00 PM
- Amarin Appoints Peter Fishman Chief Financial Officer • GlobeNewswire Inc. • 12/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:49:38 PM
FEATURED Nightfood Holdings (OTCQB: NGTF) Signs $41M LOI to Acquire Victorville Hotel as Model Property for Robotics-Enabled Hospitality • Apr 8, 2025 11:21 AM
VAYK Projects $680K 2024 Revenue with $310K Net Profit • VAYK • Apr 8, 2025 9:34 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for the Year Ended December 31, 2024 • HYDI • Apr 8, 2025 9:30 AM
Unlocking the Future of Hospitality with AI-Powered Robotics, Invaluable Industry Expertise • SYM • Apr 8, 2025 9:00 AM
UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology • UMAV • Apr 8, 2025 8:30 AM
Maybacks Global Entertainment Partners With LIME X To Bring Its iDreamCTV App To A Massive Audience • AHRO • Apr 8, 2025 8:30 AM